Terms of the transaction were not disclosed.

Zoll Medical president Jonathan Rennert said: "The acquisition of Advanced Circulatory Systems will broaden ZOLL’s product offerings with additional technologies designed to improve outcomes from cardiac arrest and other critical conditions."

Advanced Circulatory Systems CEO Mike Black said: "Becoming part of ZOLL provides Advanced Circulatory Systems with an increased infrastructure of clinical and commercial resources that will enable our technologies to reach a greater number of clinicians and positively affect more patients’ lives."

Established in 1997, ACS manufactures and markets intrathoracic pressure regulation products for patients experiencing cardiac arrest, low blood pressure, and head injury.

The firm’s products are marketed in around 25 countries across the globe, and serves military, emergency medical services, and hospital markets.

ACS’ Intrathoracic Pressure Regulation (IPR) therapy platform can be used for multiple medical conditions. It helps in protecting the heart, brain, and other vital organs when blood flow is compromised, allowing rescuers, clinicians, and caregivers the potential to return patients to a full life after critical medical emergencies.

ACS will continue to operate out of Minnesota as a part of Zoll’s core products division, after the completion of the transaction that is expected in early 2015.